• Title, Summary, Keyword: Pharmaceutical industry

Search Result 380, Processing Time 0.029 seconds

Development Strategy for Pharmaceutical Industry against Korea-United States of America FTA

  • Lee, Jae-Jun;Park, Jin-Han
    • Journal Of Oriental Pharmacy
    • /
    • v.1 no.2
    • /
    • pp.17-26
    • /
    • 2008
  • Nowadays the flow of international trade is that there seems to appear economic block significantly because most countries contract FTAs, so our market condition is changing to a severe competitive situation. Korea which has 70% of foreign dependence of trade must get involved in regionalism, and also actively promote FTA more than any other countries. FTA on February in 2006, the pharmaceutical industry are anxious. The pharmaceutical industry in Korea has recently come to a crisis that it is hard to expect a growth due to structure of profit and a change for the worse of management. If Korea-U.S. FTA are contracted in this kind of situation, domestic pharmaceutical companies will be at stake. We can anticipate that FTA with the country that has a strong competitive power like U.S. affect negatively on pharmaceutical industry, because the industry doesn't have enough self-competitiveness. Considering this kind of surroundings, we need to present the policy to enhance competitiveness for damage limitation on pharmaceutical industry by Korea-U.S. FTA. Under this background, this research has groped for a direction to strengthen the competitiveness to develop pharmaceutical industry in quality. The competitive enhancement plan is presented which is divided into the government policy part, the R&D part, and the management part. Although Korea-U.S. FTA is analyzed to wither the pharmaceutical industry, it would be thought that it is a good chance to upgrade domestic pharmaceutical industry if we make the best use of it, and also to make in roads into foreign market.

  • PDF

Analysis of the Pharmaceutical Companies' Recruitment Preference for Bachelor's Degree Holders without Prior Experience (제약업계의 학사수준 신입인력 전공 선호도 연구)

  • Han, Ah-Ram;Cheon, In-Kyung;Gil, Mi-Hyun;Yang, YouKyung;Bae, SeungJin
    • YAKHAK HOEJI
    • /
    • v.58 no.6
    • /
    • pp.397-404
    • /
    • 2014
  • The Ministry of Health and Welfare proposed the "undergraduate program specializing in pharmaceutical industry" in 2013, as part of its roadmap to assist domestic pharmaceutical companies to become the top-tier pharma companies in near future and provide skilled personnel tailored for pharmaceutical industry. However, it is not clear whether this "undergraduate program" meets the needs of pharmaceutical industry, especially when the number of pharmacy students increased from 1,200 to 1,700 per year since 2009. The purpose of this paper is to identify which educational background is preferred by pharmaceutical companies, by surveying the CEOs of domestic pharmaceutical companies and referring to recruitment advertisements shown in medical newspapers, specified by the fields within the companies. Two independent reviewers referred to recruitment session in Yakup newspaper and Dailypharm from May 2012 until January 2014, focusing on recruitments from pharmaceutical companies targeting bachelors' degree holders with no prior experience. 749 recruitments were observed during the study period, more than 90% of which were provided by domestic pharmaceutical companies, and regardless of the companies being domestic or multinational, pharmaceutical companies' preference for pharmacists was remarkable (44.3% for domestic and 65.8% for multinational), and the preference was especially high in the fields such as Medical, R&D, Market Access (regulatory affair/pricing and reimbursement), Business Development, and Marketing. Survey results showed that the need of establishing the undergraduate program specializing in pharmaceutical industry is mixed, suggesting that although there is need for the educating personnel targeting pharmaceutical industry, the undergraduate program would not be an answer due to current PEET system. Our study concludes that in the example of pharmaceutical companies' recruitments shown in medical newspapers, pharmaceutical companies prefer pharmacy major in almost all fields of the pharmaceutical companies, yet the pharmaceutical companies still perceive the gap between current bachelor's degree holders(including pharmacy majors) and the ideal personnel required for advancing to the "top-class" pharmaceutical companies.

The problems to be solved in the marketing strategy aspect by domestic pharmaceutical industry under the competintive market circumstances with multinational pharmaceutical enterprises. (다국적 제약기업과의 경쟁적시장 상황하에서의 국내제약산업의 마케팅전략상의 과제)

  • 김광철
    • Journal of the Society of Korea Industrial and Systems Engineering
    • /
    • v.17 no.31
    • /
    • pp.125-139
    • /
    • 1994
  • The purpose of this paper is to study the problems to be solved in the marketing strategy aspect by domestic pharmaceutical industry under the competitive market circumstances with multinational pharmaceutic enterprises. The major concern has been paid to the key ideas and practical methods to be needed in strengthening the competitive marketing power of domestic pharmaceutical industry against multinational pharmaceutical enterprises. In this article, the researcher is to analyze the current situations and problems of domestic pharmaceutical industry and finally the researcher is to provide the major ideas concerning the problems to be solved in the marketing strategy aspect by domestic pharmaceutical industries.

  • PDF

Synthesis and Biological Evaluation of N-(Aminopyridine) Benzamide Analogues as Histone Deacetylase Inhibitors

  • Zhang, Qing-Wei;Li, Jian-Qi
    • Bulletin of the Korean Chemical Society
    • /
    • v.33 no.2
    • /
    • pp.535-540
    • /
    • 2012
  • A series of benzamide-based histone deacetylases (HDACs) inhibitors possessing N-(aminopyridine) residue as the zinc binding site of HDAC were synthesized and evaluated. Among these derivatives, compounds with N-(2-amino-4-pyridine) benzamide moiety have been found as the most potent ones. Moreover, introduction of appropriate substituents on the terminal aryl group acting as the surface-recognition domain could significantly improve the antiproliferative activity. In particular, the compound 4k possessed favorable pharmacokinetic characteristics and exhibited potent antitumor activity on xenograft model in mice at well tolerated doses, thus suggesting a good therapeutic index.

Influence of R&D intensity on Innovation Performance in the Korean Pharmaceutical Industry: Focusing on the Moderating Effects of R&D Collaboration

  • Kim, Dae-Joong;Om, Kiyong
    • Knowledge Management Research
    • /
    • v.19 no.3
    • /
    • pp.189-223
    • /
    • 2018
  • This paper examined the effect of innovation networks comprising research and development (R&D) collaboration on innovation performance of Korean pharmaceutical firms. As co-assigned patents and co-affiliated publications are common technical outcomes of successful R&D collaboration in the pharmaceutical industry, social network analysis technique was applied for analyzing innovation networks through patent and publication data. Results of Social network analysis indicated that a small set of highly innovative firms in the Korean pharmaceutical industry were actively involved in patenting and publishing. And the analysis of structural equation model found the followings: (1) R&D intensity significantly affected patenting, publication and new drug development, (2) the activity of patenting and publishing was positively related with the innovation performance measured by new drug development, and (3) R&D collaboration in terms of degree centrality of co-patent network played significant moderating roles on the relationships among R&D intensity, patenting, and new drug development. These findings are expected to be helpful to researchers as well as policy-makers to devise innovation-promoting policies in the Korean pharmaceutical industry. Discussions and limitations of the study are provided in the last part.

An Analysis on the Effect of the Government R&D Subsidies on the Private R&D Investments : in the Case of the Pharmaceutical Industry (정부 R&D 지원의 기업 R&D 투자에 대한 효과 분석 -제약산업을 중심으로-)

  • SaKong, Jin;Shin, You-Won
    • Health Policy and Management
    • /
    • v.20 no.1
    • /
    • pp.183-203
    • /
    • 2010
  • The purpose of this study is to analyze the effect of the R&D subsidies by the government on the private firms' R&D investments in the Korean pharmaceutical industry, which are supposed to have positive effects on their economic performance. We also estimate the relationship between the private firms' R&D investments and firms' economic outcome. Empirical analysis is done by Error Component 2 Stage Least Squares(EC2SLS) estimation using 43 pharmaceutical firms' 8 years' panel data. The elasticity of the government R&D subsidies on the private R&D investments is 0.021%, which we cannot say 'efficient'. Also R&D investments have positive effects on the economic outcome of the pharmaceutical firms, as we expected. We propose several suggestions in the conclusion for the efficient way of government R&D subsidies to induce more private R&D investments.

Synthesis of Dithiolopyrrolone Derivatives and Their Leukocyte-Increasing Activities

  • Li, Chungang;Sun, Yiping;Wang, Guoping;Tan, Xiangduan
    • Bulletin of the Korean Chemical Society
    • /
    • v.35 no.12
    • /
    • pp.3489-3494
    • /
    • 2014
  • In search of new antileukopenia agents, twenty dithiolopyrrolone derivatives were synthesized and evaluated for their leukocyte-increasing activities in normal mice. Among the synthesized compounds 4-23, compounds 5 and 6 showed significant leukocyte-increasing activity ( p < 0.01), and compounds 4, 9 and 16 had a moderate effect ( p < 0.05). Compound 5 also displayed stronger leukocyte-increasing activity than that of the positive recombinant human granulocyte colony stimulating factor (rhG-CSF). Above all, compound 5 would be a potential antileukopenia agent which deserved further research.

Cold Chain Management in Pharmaceutical Industry: Logistics Perspective

  • Yoon, Yuri
    • Journal of Distribution Science
    • /
    • v.12 no.5
    • /
    • pp.33-40
    • /
    • 2014
  • Purpose - This paper aims to review cold chain management, especially in the pharmaceutical industry, to explore the cold chain process of delivering temperature-sensitive pharmaceutical products, and to identify areas for further development. Research design, data, and methodology - The paper, based on literature review and corporate analysis, reviews the development and status of the cold supply chain system, including its important role in the pharmaceutical industry. Results - Logistics in this field requires more stages than are typically needed. Due to the unique characteristics of the market, few companies can provide the services; currently, only few global companies with large networks and high technologies can afford to do so. Expanding pharmaceutical markets to meet global demand will require cold chain development, especially in "pharmerging" markets. Conclusions - Cold chain is a highly sensitive market in terms of products being carried within the chain that itself is a complex system. However, at the same time, it is a niche market with new opportunities. Hence, a sound cold chain infrastructure is needed to satisfy companies, governments, and customers for both commercial and public reasons.

A Study on Integrated Physical Distribution of the Pharmaceutical Industry in Korea (한국제약산업의 통합물류에 관한 연구)

  • Kwon, Oh-cheul;Youn, Myoung-kil;Namkung, Suk
    • Journal of Distribution Science
    • /
    • v.5 no.2
    • /
    • pp.17-34
    • /
    • 2007
  • The Korean pharmaceutical industry has many pharmaceutical companies and business acquaintances, small quantity batch production and a lot of competition products having same ingredient. Under such a situation, an integrated distribution is said to be proper to lower distribution costs and deliver effectively: However, each business has different delivery conditions, timely delivery of small quantity batch order and other particular services, etc to have problems of competition of turnover increase. The study suggests measures below to lower distribution costs and to elevate sales business efficiency. First, Joint marketing of pharmaceuticals between pharmaceutical companies. Second, Joint delivery of three or less companies having similar business scales. Third, An agreement with wholesale distributors of unified distribution of pharmaceuticals being sold much. Fourthly, Wholesale distributors' pharmaceuticals distribution services. Fifthly, Cooperation of business acquaintance. In summary, the Korean pharmaceutical industry needs an integrated distribution system. Considering characteristics of the industry, however, the small pharmaceutical companies are thought to be difficult to accept the integrated distribution because complete integrated distribution may reduce sales.

  • PDF

System Dynamics Modeling for FDA Regulation Effect of Pharmaceutical Industry (제약산업에서 FDA규제 영향에 관한 시스템 다이내믹스 모델링: FDA규제가 R&D비용에 미치는 영향을 중심으로)

  • Ko, Seong-Pil;Choi, Jeong-Hwan;Nam, Dong-Wok;Lee, Jeong-Dong
    • Korean System Dynamics Review
    • /
    • v.13 no.4
    • /
    • pp.57-80
    • /
    • 2012
  • This research studies effect of FDA regulations in pharmaceutical industry on new drug development. System dynamics is implemented to demonstrate dynamic relationship between FDA regulations and R&D costs, firm's profits, sales. This research is focused on clinical trials of new medical entity process 50~60% portion of total development cost. Simulation results say that firm's profit is more sensitive to increasing the regulation than alleviating the regulation and effect of regulation policy make different result depending on the intensity of regulation and policy direction. Our simulation model provides the instrumental means for the policy makers and strategic decision in pharmaceutical industry.

  • PDF